Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in Altimmune, Inc. (NASDAQ:ALT) by 93.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 155,741 shares of the company’s stock after purchasing an additional 75,064 shares during the period. Barclays PLC owned 0.22% of Altimmune worth $956,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after buying an additional 74,194 shares during the last quarter. Bellevue Group AG increased its holdings in shares of Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after acquiring an additional 263,660 shares during the period. Dimensional Fund Advisors LP lifted its position in Altimmune by 142.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Altimmune by 28.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 243,808 shares of the company’s stock valued at $1,621,000 after purchasing an additional 54,154 shares during the period. Finally, Exchange Traded Concepts LLC grew its position in Altimmune by 74.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock worth $1,331,000 after purchasing an additional 92,498 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Analyst Upgrades and Downgrades

ALT has been the topic of a number of recent analyst reports. UBS Group assumed coverage on Altimmune in a report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th. Finally, Stifel Nicolaus started coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.71.

Altimmune Stock Down 8.1 %

Shares of ALT stock opened at $6.23 on Wednesday. The stock has a 50-day simple moving average of $8.08 and a 200 day simple moving average of $7.20. The stock has a market capitalization of $443.11 million, a P/E ratio of -4.02 and a beta of 0.22. Altimmune, Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.84.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The company had revenue of $0.01 million for the quarter. During the same period in the prior year, the firm earned ($0.39) EPS. On average, sell-side analysts anticipate that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.